看看方向，单双抗新靶点，细胞和基因疗法？疫苗?那些年能最终上桌？拭目以待。
1. B7-H4抗体药物偶联物（Emi-Le）
2. PD-L1/4-1BB双特异性抗体（LBL-024）
3. PRAME TCR-T细胞疗法（IMA203）
4. CLDN6×CD3 mRNA双特异性抗体
5. KRAS G12D抑制剂
6. WT1口服癌症疫苗
7. [²¹²Pb] VMT-α-NET
8. IL-2α偏向性融合抗体
9. SYNC-T：原位疫苗
10. KRAS G12C联合疗法
1. Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC.
Emiltatug ledadotin（Emi-Le）：一种用于三阴性乳腺癌Ⅰ期剂量扩展研究的B7-H4靶向多聚合成抗体偶联物
Time: 09:00-12:00, June 02, 2025 | On-demand, Poster
2. Initial phase 1 dose escalation data for emiltatug ledadotin (Emi-Le): A novel B7-H4-directed dolasynthen antibody-drug conjugate.
新型B7-H4靶向多聚合成抗体偶联物Emiltatug ledadotin（Emi-Le）的Ⅰ期剂量递增初步数据
Time: 08:00-08:06, June 02, 2025 | On-demand, Oral
3. Assessment of efficacy of LBL-024: A novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase lb/ll trial.
评估LBL-024（一种新型PD-L1/4-1BB双特异性抗体）联合依托泊苷/铂类化疗治疗初治晚期肺外神经内分泌癌（EP-NEC）的多中心Ⅰb/Ⅱ期试验疗效
Time: 15:00-15:12, May 31, 2025 | Live, Oral
4. Phase 1 clinical update of IMA203: An autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.
IMA203（一种靶向PRAME的自体TCR-T疗法）用于PD1难治性转移性黑色素瘤患者的Ⅰ期临床更新
Time: 17:24-17:36, May 31, 2025 | Live, Oral
5. SUPRAME: A phase 3 trial comparing IMA203: An engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator's choice in patients with previously treated advanced cutaneous melanoma.
SUPRAME：一项比较IMA203（工程化TCR-T疗法）与研究者选择方案治疗既往治疗过的晚期皮肤黑色素瘤的Ⅲ期试验
Time: 13:30-16:30, June 02, 2025 | On-demand, Poster
6. First-in-human phase 1/ll trial evaluating BNT142: A first-in-class mRNA encoded, bispecific antibody targeting Claudin6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.
评估BNT142（一种mRNA编码的CLDN6×CD3双特异性抗体）用于CLDN6阳性晚期实体瘤患者的首次人体Ⅰ/Ⅱ期试验
Time: 15:12-15:24, May 31, 2025 | Live, Oral
7. Efficacy and safety results of IB1363: A first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein in patients (pts) with immunotherapy-treated, advanced acral and mucosal melanoma.
IB1363（一种PD-1/IL-2α偏向性双特异性抗体融合蛋白）用于接受过免疫治疗的晚期肢端和黏膜黑色素瘤患者的有效性和安全性结果
Time: 15:24-15:36, May 31, 2025 | Live, Oral
8. Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab: In patients with advanced colorectal cancer.
IBI363单药或联合贝伐珠单抗治疗晚期结直肠癌患者的有效性和安全性
Time: 10:33-10:45, June 01, 2025 | Live, Symposia
9. First-in-class PD-1/IL-2bispecific antibody IB1363: In patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).
IB1363（一种PD-1/IL-2双特异性抗体）用于接受过免疫治疗的晚期非小细胞肺癌患者的研究
Time: 09:57-10:09, June 03, 2025 | On-demand, Symposia
10. Clinical responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
SYNC-T疗法（瘤内免疫治疗的原位个性化癌症疫苗）用于转移性去势抵抗性前列腺癌（mCRPC）患者的临床反应
Time: 16:12-16:24, May 31, 2025 | Live, Oral
11. A first-in-human phase I/ll study of GFH375: A highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors.
GFH375（一种口服KRAS G12D抑制剂）用于KRAS G12D突变晚期实体瘤患者的首次人体Ⅰ/Ⅱ期研究
Time: 08:36-08:42, June 02, 2025 | On-demand, Oral
12. Preliminary results from a first-in-human, phase I/ll study of VLS-1488: An oral KIF18A inhibitor in patients with advanced solid tumors.
VLS-1488（一种口服KIF18A抑制剂）用于晚期实体瘤患者的首次人体Ⅰ/Ⅱ期研究初步结果
Time: 08:30-08:36, June 02, 2025 | On-demand, Oral
13. Phase 1 study of B440: An oral Bifidobacterium-engineered WT1 cancer vaccine in patients with metastatic urothelial cancer.
B440（一种口服双歧杆菌工程化WT1癌症疫苗）用于转移性尿路上皮癌患者的Ⅰ期研究
Time: 16:24-16:36, May 31, 2025 | Live, Oral
14. [²¹²Pb]VMT-α-NET therapy in SSTR2-expressing NETs: Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants.
[²¹²Pb]VMT-α-NET疗法用于表达生长抑素受体2（SSTR2）的神经内分泌肿瘤（NETs）：1年随访后剂量限制性毒性（DLT）观察及扩展参与者初步报告
Time: 16:09-16:21, May 30, 2025 | Live, Oral
苏公网安备32059002004080号
